in biochemistry from the University of Maryland, College Park, where he graduated summa cum laude and was a member of the Phi Beta Kappa Society. For more information about Tessera, please visit Contact. where he was responsible for leading research in multiple areas, including clinical genomics, molecular profiling, and experimental medicine. Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Mike was previously Senior Director at Merck & Co., Inc. As Senior Vice President he oversaw the company’s clinical development efforts across all therapeutic areas, including oncology, inflammation, neuroscience, cardiovascular, and metabolic disorders. Prior to joining AbbVie, Mike served in roles of increasing responsibility at Amgen, Inc., leading to his appointment as Senior Vice President, Global Development and Chief Medical Officer. Under his leadership, AbbVie achieved several important new molecular entity approvals and built leading franchises in hematologic oncology, immunology, and neuroscience. During his tenure at AbbVie, Mike oversaw a rapid expansion of AbbVie’s pipeline and built critical new capabilities in areas such as genetics and genomics, computational biology, and precision medicine. As we write the FutureofGeneticMedicine, we aim to make the broadest possible impact for patients through our LNP delivery. Mike joined Tessera from AbbVie where he was Vice Chairman and President responsible for research and development and the corporate strategy office. On Friday, Tessera Therapeutics announced preliminary data from five preclinical programs using its gene writers to tweak specific letters or insert entirely new sequences of DNA. Mike brings more than two decades of biopharmaceutical leadership and significant contributions to the research, development, registration, and commercialization of more than a dozen approved therapies. Michael joined Tessera in 2022 as Chief Executive Officer and a CEO-Partner at Flagship Pioneering.
0 kommentar(er)
